Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases

Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases IntroductionPrurigo is a common primary chronic skin disease which highly affects quality of life. Clinical subtypes include prurigo nodularis and excoriated (simplex) prurigo, often associated in the same patients. A minor eczematous component may sometimes be associated, but prurigo differs from pruritus associated with other dermatoses such as bullous pemphigoid, atopic dermatitis, Sézary syndrome and scabies. Therapeutic recommendations of prurigo are scarce due to the lack of previously published strong data. Topical corticosteroids, H1‐antihistamine drugs, moisturizing ointments and phototherapy may be non‐effective. Thalidomide has shown clinical benefit, but its long‐term use is limited by side‐effects. Consequently, treatment may be challenging in patients with difficult‐to‐treat prurigo, that is, with failure of conventional therapies.Methotrexate (MTX) is a folic acid antagonist that has proven its efficacy and good tolerance profile in inflammatory dermatoses (atopic dermatitis, psoriasis, bullous pemphigoid). Only one study investigating the efficacy of MTX in 13 patients with prurigo, showing encouraging results, has been published. The aim of our study was to assess the efficacy and safety of MTX in the treatment of difficult‐to‐treat prurigo in a larger series of patients.Materials and methodsIn this retrospective, multicentre study, cases were recruited within six French university dermatology departments, using the coding of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Loading next page...
 
/lp/wiley/treatment-of-prurigo-with-methotrexate-a-multicentre-retrospective-gCv1zE0LAX
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14646
Publisher site
See Article on Publisher Site

Abstract

IntroductionPrurigo is a common primary chronic skin disease which highly affects quality of life. Clinical subtypes include prurigo nodularis and excoriated (simplex) prurigo, often associated in the same patients. A minor eczematous component may sometimes be associated, but prurigo differs from pruritus associated with other dermatoses such as bullous pemphigoid, atopic dermatitis, Sézary syndrome and scabies. Therapeutic recommendations of prurigo are scarce due to the lack of previously published strong data. Topical corticosteroids, H1‐antihistamine drugs, moisturizing ointments and phototherapy may be non‐effective. Thalidomide has shown clinical benefit, but its long‐term use is limited by side‐effects. Consequently, treatment may be challenging in patients with difficult‐to‐treat prurigo, that is, with failure of conventional therapies.Methotrexate (MTX) is a folic acid antagonist that has proven its efficacy and good tolerance profile in inflammatory dermatoses (atopic dermatitis, psoriasis, bullous pemphigoid). Only one study investigating the efficacy of MTX in 13 patients with prurigo, showing encouraging results, has been published. The aim of our study was to assess the efficacy and safety of MTX in the treatment of difficult‐to‐treat prurigo in a larger series of patients.Materials and methodsIn this retrospective, multicentre study, cases were recruited within six French university dermatology departments, using the coding of

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off